Role of posaconazole in the management of oropharyngeal and esophageal candidiasis

References

• AlbengresELe LouetHTillementJPSystemic antifungal agents: drug interactions of clinical significanceDrug Saf19981883979512916
   PubMed Web of Science ®Google Scholar
• AllyRSchurmannDKreiselWA randomized double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patientsClin Infect Dis20013314475411577374
   PubMed Web of Science ®Google Scholar
• BarchiesiFMorbiducciVAncaraniFEmergence of oropharyngeal candidiasis caused by non-albicans species of Candida in HIV-infected patientsEur J Epidemiol19939455568243605
   PubMed Web of Science ®Google Scholar
• BaroneJAMoskovitzBLGuarnieriJEnhanced bioavailability of itraconazole in hydroxypropyl-β-cyclodextrin solution compared with capsules in healthy volunteersAntimicrob Agents Chemother1998421862659661037
   PubMed Web of Science ®Google Scholar
• ChauASMendrickCASabatelliFJApplication of real-time quantitive PCR to molecular analysis of Candida albicans strains exhibiting reduced susceptibility to azolesAntimicrob Agents Chemother20044821243115155210
   PubMed Web of Science ®Google Scholar
• CokerRJFisherMTomlinsonDRManagement of mycoses associated with HIV diseaseInt J STD AIDS19956408128845397
   PubMed Web of Science ®Google Scholar
• ComoJADismukesWEOral azole drugs as systemic antifungal therapyN Eng J Med199433026372
   PubMed Web of Science ®Google Scholar
• ComoJDismukesWEDismukesWEPappasPGSobelJDAzole antifungal drugsClinical Mycology20031New York, NYOxford University Press6487
   Google Scholar
• CourtneyRLaughlinMGontzHSingle-dose pharmacokinetics of posaconazole in subjects with various degrees of chronic liver disease2000bAnnual Meeting of American Association of Pharmaceutical ScientistsOctober 29-November 2Indianapolis, IN
   Google Scholar
• CourtneyRMartinhoMLimJEvaluation of the effect of age, weights, race, and gender on posaconazole plasma concentrations in HIV-infected patients2000a3rd European Congress of Clinical Microbiology and Infectious DiseasesMay 10–13Glasgow, Scotland
   Google Scholar
• CourtneyRPaiSLaughlinMPharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adultsAntimicrob Agents Chemother2003b4727889512936975
   PubMed Web of Science ®Google Scholar
• CourtneyRSansoneACalzettaAThe effect of a nutritional supplement (Boost Plus) on the oral bioavailability of posaconazole2003c43rd Interscience Conference on Antimicrobial Agents and ChemotherapySeptember 14–17Chicago, IL
   Google Scholar
• CourtneyRSansoneAKantesariaBEffect of ethnicity on the pharmacokinetics of posaconazole in healthy volunteers2003d43rd Interscience Conference on Antimicrobial Agents and ChemotherapySeptember 14–17, 2003Chicago, IL
   Google Scholar
• CourtneyRSansoneARadwanskiERelative oral bioavailability of three formulations of posaconazole in healthy volunteers: basis for clinical development of the suspension2003a13th European Congress of Clinical Microbiology and Infectious DiseasesMay 10–13Glasgow, Scotland
   Google Scholar
• CourtneyRSansoneAStatkevichPEffect of age and gender on the pharmacokinetics of posaconazole in healthy volunteers2003e43rd Interscience Conference on Antimicrobial Agents and ChemotherapySeptember 14–17Chicago, IL
   Google Scholar
• CourtneyRSansoneAStatkavichPPharmacokinetics of posaconazole in subjects with varying degrees of renal insufficiency2003f13th European Congress of Clinical Microbiology and Infectious DiseasesMay 10–13Glasgow, Scotland
   Google Scholar
• CourtneyRWexlerDRadwanskiEEffect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adultsBr J Clin Pharmacol2004572182214748822
   PubMed Web of Science ®Google Scholar
• DarouicheROOropharyngeal and esophageal candidiasis in immunocompromised patients: treatment issuesClin Infect Dis199826259749502438
   PubMed Web of Science ®Google Scholar
• DeWitSWeertsDGoossensHComparison of fluconazole and ketoconazole for oropharyngeal candidiasis in AIDSLancet1989174682564563
   PubMed Web of Science ®Google Scholar
• DupontBDenningDWMarriotDMycosis in AIDSJ Med Vet Mycology199432Suppl6577
   Google Scholar
• EzzetFWexlerDCourtneyRThe oral bioavailability of posaconazole in fasted healthy subjects: basis for clinical dosage recommendationsClin Pharmacokinet2007In press
   Web of Science ®Google Scholar
• GraybillJRVazquezJDarouicheROItraconazole oral solution: a novel and effective treatment for oropharyngeal candidiasis in HIV/AIDS patientsAm J Med19981043399528717
   PubMed Web of Science ®Google Scholar
• GrollAHWalshTGDismukesWEPappasPGSobelJDCell wall synthesis inhibitors: echinocandins and nikkomycinsClinical Mycology20031New York, NYOxford University Press88103
   Google Scholar
• HayRJOverview of studies of fluconazole in oropharyngeal candidiasisRev Infect Dis199012Suppl 3S33472184511
   PubMedGoogle Scholar
• HeimarkLShipkovaPGreeneJMechanism of azole antifungal activity as determined by liquid chromatographic/mass spectrometric monitoring of ergosterol biosynthesisJ Mass Specgrom2002372659
   PubMed Web of Science ®Google Scholar
• HerbrechtRPosaconazole: a potent extended spectrum triazole antifungal for the treatment of serious fungal infectionsInt J Clin Pract2004586122415311563
   PubMed Web of Science ®Google Scholar
• HippocratesCAAdamsFEpidemics, Book 31939BaltimoreWilliams and Wilkins
   Google Scholar
• HonigPKWorthamDCZamaniKTerfenadine-ketoconazole interaction. Pharmacokinetic and electrocardiographic consequencesJAMA1993269151388445813
   PubMed Web of Science ®Google Scholar
• HostetlerJSHansonLHStevensDAEffect of cyclodextrin on the pharmacology of antifungal oral azolesAntimicrob Agents Chemother199236477801605615
   PubMed Web of Science ®Google Scholar
• HughesWTBartleyDLPattersonGGKetoconazole and candidiasis: a controlled studyJ Infect Dis1983147106036304203
   PubMed Web of Science ®Google Scholar
• ImamNCarpenterCCMayerKHFisherASteinMDanforthSBHierarchical pattern of mucosal candida infections in HIV-seropositive womenAm J Med19908914261974383
   PubMed Web of Science ®Google Scholar
• JensenKBStenderupAThomsenJBEsophageal moniliasis in malignant neoplastic diseaseActa Med Scand1964175455914149650
   PubMed Web of Science ®Google Scholar
• JohnstonRDChickEWJohnstonNSAsymptomatic quantitative increase of Candida albicans in the oral cavity: predisposing conditionsSouth Med J196760124474862923
   PubMed Web of Science ®Google Scholar
• KoletarSLRussellJAFassRJComparison of oral fluconazole and clotrimazole troches as treatment for oral candidiasis in patients infected with human immunodeficiency virusAntimicrob Agents Chemother199034226782073120
   PubMed Web of Science ®Google Scholar
• KowalskySFDixonDMFluconazole: a new antifungal agentClin Pharm199110179942040125
   PubMedGoogle Scholar
• KozininPJTaschdjianCLDragutskyDTherapy of oral thrush: a comparative evaluation of gentian violet, mycostatin and amphotericin BMonogr Ther195721624
   Google Scholar
• KrieterPFlanneryBMusickTPharmacokinetics and excretion of 14C posaconazole following oral administration in healthy male subjects200242nd Interscience Conference on Antimicrobial Agents and ChemotherapySeptember 27–30San Diego, CA
   Google Scholar
• LiXBrownChauASChanges in susceptibility to posaconazole in clinical isolates of Candida albicans J Antimicorb Chemother2004537480
   PubMed Web of Science ®Google Scholar
• McCarthyGMMackieIDKovalJFactors associated with increased frequency of HIV-related oral candidiasisJ Oral Pathol Med19912033261680189
   PubMed Web of Science ®Google Scholar
• MaenzaJRKerulyJCMooreRDRisk factors for fluconazole-resistant candidiasis in human immunodeficiency virus-infected patientsJ Infect Dis1996173219258537662
   PubMed Web of Science ®Google Scholar
• MeunierFAounMGerardMTherapy of oropharyngeal candidiasis in the immunocompromised host: a randomized double-blind study of fluconazole vs. ketoconazoleRev Infect Dis199012Suppl 3S36482184513
   PubMedGoogle Scholar
• MeyerJMRodvoldKADrug biotransformation by the cytochrome P-450 enzyme systemInfect Med199664524
   Google Scholar
• MooreRDChaissonRENatural history of opportunistic disease in an HIV-infected urban clinical cohortAnn Intern Med1996124633428607591
   PubMed Web of Science ®Google Scholar
• MunayyerHKMannPAChauASPosaconazole is a potent inhibitor of sterol 14 alpha demethylation in yeasts and moldsAntimicrob Agents Chemother200448369015388421
   PubMed Web of Science ®Google Scholar
• MurrayPAKoletarSLMallegolIItraconazole oral solution versus clotrimazole troches for the treatment of oropharyngeal candidiasis in immunocompromised patientsClin Ther199719471809220211
   PubMed Web of Science ®Google Scholar
• OddsFCCandida and CandidosisA review and bibliography1988LondonBaillière Tindall
   Google Scholar
• Ostrosky-ZeichnerLRexJHPappasPGAntifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United statesAntimicrob Agents Chemother20034731495414506023
   PubMed Web of Science ®Google Scholar
• PappasPGRexJHSobelJDGuidelines for treatment of candidiasisClin Infect Dis2004381618914699449
   PubMed Web of Science ®Google Scholar
• Pfizer, IncPackage insert2003NY, New York
   Google Scholar
• PiscitelliSCFlexnerCMinorJRDrug interactions in patients infected with human immunodeficiency virusClin Infect Dis199623685938909827
   PubMed Web of Science ®Google Scholar
• PitisuttithumPGaona-FloresVNegroniREfficacy of posaconazole in treatment of central nervous system fungal infections: results of an open-label study200343rd Interscience Conference on Antimicrobial Agents and ChemotherapySeptember 14–17Chicago, IL
   Google Scholar
• PonsVGreenspanDDebruinMTherapy for oropharyngeal candidiasis in HIV-infected patients: a randomized, prospective multicenter study of oral fluconazole versus clotrimazole trochesJ Acquir Immune Defic Syndr19936131168254467
   PubMed Web of Science ®Google Scholar
• PonsVGreenspanDLozada-NurFOropharyngeal candidiasis in patients with AIDS: randomized comparison of fluconazole versus nystatin oral suspensionsClin Infect Dis199724120479195083
   PubMed Web of Science ®Google Scholar
• QuintilianiROwensNJQuerciaRATreatment and prevention of oropharyngeal candidiasisAm J Med199477Suppl 4D4486093531
   PubMed Web of Science ®Google Scholar
• RaadIIHachemRYHerbrechtRPosaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditionsClin Infect Dis200642139816619151
   PubMed Web of Science ®Google Scholar
• ReefSEMayerKHOpportunistic candidal infections in patients infected with human immunodeficiency virus: prevention issues and prioritiesClin Infect Dis199521Suppl 1S991028547520
   PubMed Web of Science ®Google Scholar
• SabatelliFJPatelRMannPAIn vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts. Approximately 18,000 strains of clinically significant yeasts and mouldsAntimicrob Agents Chemother200650200916723559
   PubMed Web of Science ®Google Scholar
• Schering CorporationPackage insert2006Kenilworth, NJ
   Google Scholar
• ScottBBJenkinsDGastro-oesophageal candidiasisGut19822313797068036
   PubMed Web of Science ®Google Scholar
• ShectmanLBFunaroLRobinTClotrimazole treatment of oral candidiasis in patients with neoplastic diseaseAm J Med198476914
   Web of Science ®Google Scholar
• SilvermanSJrGalloJWMcKnightMLClinical characteristics and management responses in 85 HIV-infected patients with oral candidiasisOral Surg Oral Med Oral Pathol Oral Radiol Endod19968240278899777
   PubMed Web of Science ®Google Scholar
• SkiestDJVazquezJAAnsteadGMPosaconazole for the treatment of azole-refractory oropharyngeal and esophageal candidiasis in subjects with HIV-infectionClin Infect Dis2006In press
   Web of Science ®Google Scholar
• TuckerRMDenningDWHansonLHInteractions of azoles with rifampin, phenytoin, and carbamazepine: in vitro and clinical observationsClin Infect Dis199214165741315160
   PubMed Web of Science ®Google Scholar
• UllmannAJCornelyOABurchardTPosaconazole vs fluconazole for prophylaxis of invasive fungal infections in allogenic hematopoietic stem cell transplant recipients with graft-versus-host disease2005Poster presented at the 46th Interscience Conference on Antimicrob Agents Chemother
   Google Scholar
• van BurikJAHareRSSolomonFPosaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 casesClin Infect Dis200642e6116511748
   PubMed Web of Science ®Google Scholar
• Van de VeldeVJSVan PeerAPHeykantsJJPEffect of food on the pharmacokinetics of a new hydroxypropyl-β-cyclodextrin formulation of itraconazolePharmacotherapy19961642488726601
   PubMed Web of Science ®Google Scholar
• van’t WoutJWFluconazole treatment of candidal infections caused by non-albicans Candida speciesEur J Clin Microbiol Infect Dis199615238428740860
   PubMed Web of Science ®Google Scholar
• VazquezJASobelJDEpidemiologic overview of resistance to oral antifungal agents in the immunocompromised host [abstract]Excerpta Medica1997111 Abstract
   Google Scholar
• VazquezJAOptions for the management of mucosal candidiasis in patients with AIDS and HIV infectionPharmacotherapy19991976879917080
   PubMed Web of Science ®Google Scholar
• VazquezJASobelJDDismukesWEPappasPGSobelJDCandidiasisClinical Mycology20031New York, NYOxford University Press14387
   Google Scholar
• VazquezJASkiestDJNietoLA multicenter randomized trial evaluating posaconazole versus fluconazole for the treatment of oropharyngeal candidiasis in subjects with HIV/AIDSClin Infect Dis20064211798616575739
   PubMed Web of Science ®Google Scholar
• VazquezJASkiestDJTissot-DupontHSafety and efficacy of posaconazole in the long-term treatment of azole-refractory oropharyngeal and esophageal candidiasis in subjects with HIV infectionHIV Clin Trials2007In press
   Web of Science ®Google Scholar
• VenkatakrishnanKVon MoltkeLLGreenblattDJEffects of the antifungal agents on oxidative drug metabolism: clinical relevanceClin Pharmacokinet2000381118010709776
   PubMed Web of Science ®Google Scholar
• WexlerDLaughlinMCourtneyREffect of posaconazole on cytochrome P450 enzymes: a randomized, open-label, two-way crossover studyEur J Pharm Sci20042164515066665
   PubMed Web of Science ®Google Scholar
• WilcoxCMDarouicheROLaineLA randomized, double-blind comparison of itraconazole oral solution and fluconazole tablets in the treatment of esophageal candidiasisJ Infect Dis1997176227329207371
   PubMed Web of Science ®Google Scholar
• XiaoLMadisonCChauiASThree-dimensional models of wild-type and mutated forms of cytochrome P450 14 alpha-sterol demethylases from Aspergillus fumigatus and Candida albicans provide insights into posaconazole bindingAntimicrob Agents Chemother2004485687414742211
   PubMed Web of Science ®Google Scholar